19054-Breast Cancer-NA-129

Breast Cancer

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number:

  • Address

1800 N Williams St, Suite 200
Denver, CO 80218
P: (303) 388-4876

Search by practice name, trial titles, indicators and specific disease types.